Outcomes
SECONDARY
The primary outcome was HIV-1 p24 concentration in participants' foreskin tissue up to day 15 following The secondary outcomes included p24 concentrations in PBMCs; drug concentration in foreskin tissue, foreskin CD4+/CD4-cells, blood (plasma and PBMCs); additional effect of 